These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32482838)

  • 1. What is the role of axonal ion channels in multiple sclerosis?
    Correale J; Marrodan M; Benarroch EE
    Neurology; 2020 Jul; 95(3):120-123. PubMed ID: 32482838
    [No Abstract]   [Full Text] [Related]  

  • 2. Axonal protection in multiple sclerosis--a particular need during remyelination?
    Smith KJ
    Brain; 2006 Dec; 129(Pt 12):3147-9. PubMed ID: 17132643
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium channel blockers and axonal protection in neuroinflammatory disease.
    Waxman SG
    Brain; 2005 Jan; 128(Pt 1):5-6. PubMed ID: 15596795
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
    Craner MJ; Damarjian TG; Liu S; Hains BC; Lo AC; Black JA; Newcombe J; Cuzner ML; Waxman SG
    Glia; 2005 Jan; 49(2):220-9. PubMed ID: 15390090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine.
    Kapoor R
    J Neurol Sci; 2008 Nov; 274(1-2):54-6. PubMed ID: 18486153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ion channels as drug targets in central nervous system disorders.
    Waszkielewicz AM; Gunia A; Szkaradek N; Słoczyńska K; Krupińska S; Marona H
    Curr Med Chem; 2013; 20(10):1241-85. PubMed ID: 23409712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis.
    Krishnan AV; Kiernan MC
    Mult Scler; 2013 Apr; 19(4):385-91. PubMed ID: 23077091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences.
    Leanza L; Managò A; Zoratti M; Gulbins E; Szabo I
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt B):1385-97. PubMed ID: 26658642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ion channel blockers on basal hippocampal monoamine levels in freely moving diabetic and non-diabetic rats.
    Misumi Y; Yamato T; Obata T; Aomine M
    Int J Neurosci; 2008 Jun; 118(6):761-80. PubMed ID: 18465423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The calcium channel blocker--a new addition to the symptomatic therapy of multiple sclerosis].
    Ditzen G; Gerst F; Hänsel W; Koppenhöfer E
    Dtsch Med Wochenschr; 1995 Jul; 120(30):1061-2. PubMed ID: 7628322
    [No Abstract]   [Full Text] [Related]  

  • 11. Ion channels as molecular targets in prostate cancer.
    Trepel JB
    Clin Prostate Cancer; 2003 Dec; 2(3):188-9. PubMed ID: 15040864
    [No Abstract]   [Full Text] [Related]  

  • 12. [Membrane mechanisms of effects of antihypoxic agents bemethyl and almide on neurons of Mollusca].
    Vislobokov AI; Marysheva VV; Shabanov PD
    Eksp Klin Farmakol; 2003; 66(6):9-11. PubMed ID: 14743702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaphorin3A facilitates axonal transport through a local calcium signaling and tetrodotoxin-sensitive voltage-gated sodium channels.
    Yamane M; Yamashita N; Yamamoto H; Iizuka A; Shouji M; Usui H; Goshima Y
    Biochem Biophys Res Commun; 2012 Jun; 422(2):333-8. PubMed ID: 22575508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecules targeting sodium and calcium channels for neuropathic pain.
    Bear B; Asgian J; Termin A; Zimmermann N
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):543-61. PubMed ID: 19562650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel method to assess cardiac electrophysiology in the rat: characterization of standard ion channel blockers.
    Regan CP; Cresswell HK; Zhang R; Lynch JJ
    J Cardiovasc Pharmacol; 2005 Jul; 46(1):68-75. PubMed ID: 15965357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeted ion channel therapy: Can it be an alternative choice for esophageal cancer patients?
    Zhang G; Wang X; Xue Q
    Med Hypotheses; 2018 Aug; 117():59-62. PubMed ID: 30077199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium channel blockers from Ruta--a new approach for the treatment of multiple sclerosis.
    Bohuslavizki KH; Hänsel W; Kneip A; Koppenhöfer E; Reimers A
    Gen Physiol Biophys; 1992 Oct; 11(5):507-12. PubMed ID: 1291451
    [No Abstract]   [Full Text] [Related]  

  • 18. Approaches to the development of pharmacological interventions in multiple sclerosis.
    Davis FA; Schauf CL
    Adv Neurol; 1981; 31():505-10. PubMed ID: 6275674
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status.
    Waxman SG
    Nat Clin Pract Neurol; 2008 Mar; 4(3):159-69. PubMed ID: 18227822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.